Bayer And CRISPR Form Cutting Edge Gene Editing JV
This article was originally published in Scrip
A big pharma has entered the fray, teaming up with a biotech to create the first long-term stand-alone joint venture exploring the gene-editing technology Crispr-Cas9. German conglomerate Bayer AG and Switzerland-based CRISPR Therapeutics have created a joint venture that will explore the technology in three therapeutic areas.
Register for our free email digests: